| 2021-BAO-69243 | |
| Researchers at Purdue University have developed chimeric antigen receptor (CAR) neutrophils for the targeted treatment of cancer. Currently, cell therapies for cancer such as CAR T cells and CAR natural killer cells show promise. However, neutrophils, the most abundant white blood cell type, have not been used in cell therapy due to their short half-life and resistance to genetic modification. The Purdue researchers genetically engineered human pluripotent stem cells which they successfully differentiated into CAR neutrophils. The researchers demonstrated their CAR neutrophils in vitro, showing the power to kill multiple cancer cell types, with the highest cell killing efficiency against a glioblastoma cell line. Advantages: -Off-the-shelf source of cells -Derived from human pluripotent stem cells -Chemically-defined, GMP-compatible platform -High tumor cell killing ability in vitro Potential Applications: -Neutropenia treatment -Cancer therapy -Targeted drug delivery -Glioblastoma therapy Technology Validation -Killing efficiency was tested in vitro against multiple cancer cell lines. In vivo tumor-killing validation is ongoing Publication: Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy Chang et al., 2022, Cell Reports 40, 111128 July 19, 2022 https://doi.org/10.1016/j.celrep.2022.111128 |
|
|
|
|
Jun 9, 2023
NATL-Patent
United States
(None)
(None)
Dec 10, 2021
PCT-Patent
WO
(None)
(None)
Dec 10, 2021
NATL-Patent
Canada
(None)
(None)
Dec 10, 2021
NATL-Patent
Australia
(None)
(None)
Dec 10, 2021
NATL-Patent
China
(None)
(None)
Dec 10, 2021
NATL-Patent
Europe
(None)
(None)
Dec 10, 2021
NATL-Patent
Japan
(None)
(None)
Dec 11, 2020
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
